z-logo
open-access-imgOpen Access
Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
Author(s) -
Steven Tisseverasinghe,
M. K. Tolba,
Fred Saad,
Gwénaëlle Gravis,
Boris Bahoric,
Tamim Niazi
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.22.00883
Subject(s) - medicine , prostate cancer , luteinizing hormone , hormone , cancer , hormone therapy , prostate , hormone receptor , oncology , endocrinology , gynecology , breast cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here